Margulis leaves MMI Medical
MMI Medical president and CEO Alan Margulis has left the Corona, CA, company, which is the parentof independent service organization InnoServ Technologies. Margulisand MMI's board parted ways several days after MMI posted financialresults for the third
MMI Medical president and CEO Alan Margulis has left the Corona, CA, company, which is the parentof independent service organization InnoServ Technologies. Margulisand MMI's board parted ways several days after MMI posted financialresults for the third quarter of fiscal 1995 (end-January). MMIcofounder Dr. Samuel Salen was tapped as interim president andCEO until a replacement for Margulis is found.
MMI announced Margulis' departure on March 13, a few days afterit reported quarterly numbers that showed revenue up but incomedown. Sales for the quarter were $10.6 million, compared to $7.8million in the third quarter of fiscal 1994. The company had netincome for the quarter of $121,000, which halted a streak of twoconsecutive losing quarters. Net income was $421,000 in the sameperiod the year before. MMI had a net loss of $1 million for itsfirst nine months of 1995, against a net gain of $1.5 millionat the same point in 1994.
MMI bought Mediq Equipment and Maintenance Services (MEMS)last year, merged it into its R Squared subsidiary and renamedthe new ISO InnoServ (SCAN 10/12/94 and 6/1/94).
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
